Much of the cancer chemopreventive properties of green tea are mediated by EGCG. Cancer cells survive by using multiple pathways. But EGCG is so powerful, it cuts those pathways off. Apparently, EGCG functions as a powerful antiangiogenic and antitumor agent and as a modulator of tumor cell response to chemotherapy. EGCG induces apoptosis and promotes cell growth arrest by altering the expression of cell cycle regulatory proteins, activating killer caspases, and suppressing oncogenic transcription factors and pluripotency maintain factors.
EGCG is also able to induce proteasome inhibition in whole cells. Since the inhibition of the proteasome blocks the activation of NF-kB, it is logical to conclude that proteasome inhibitors such as EGCG would have a strong therapeutic effect against cancer, lymphoma and leukemia.
Revisiting the role of EGCG-MAX (Pure Liquid 95% EGCG) in the treatment of all cancers and leukemias
Many studies have investigated the topical use of EGCG to treat cancer. But, human skin is a remarkably efficient barrier designed to keep our insides in and the outside out. The modulation of this efficient barrier’s properties, including its permeability to biologically active agents is the prime target for various dermal and transdermal delivery approaches.
Here is the good news. Topical EGCG-MAX has unique chemical properties that allow it to readily penetrate the skin. This is a unique way to treat cancer cells and leave healthy cells untouched. Topical EGCG-MAX can readily enter the body by absorption via a topical application. It will enter the lymphatic system instead of the blood. This is amazing. It works.
Cancer can appear in the lymph nodes in two ways: it either starts there or spreads there from somewhere else. Cancer that starts in the lymph nodes is called lymphoma. The lymphatics are the primary conduit for the dissemination of metastases from many solid tumours. Distant organ metastasis can occur through both blood vascular and lymphatic vascular routes.
Primary tumors induce new lymphatic vessel growth in draining lymph nodes before metastasis. Increased lymphatic flow and dilation of collecting vessels contributes sentinel lymph node metastasis. The remarkable enlargement of sinusoidal lymphatic endothelium might facilitate tumor cell transport to the lymph nodes, and potentially contribute to the migration, residence, and/or survival of metastatic tumor cancer stem cells by inducing a specific tumor microenvironment. Growth of metastasis inside sentinel lymph nodes may lead to lymphatic dysfunction and a rerouting of flow and metastasis towards alternate lymph nodes.
Lymphatic delivery of EGCG is expected to provide advantages over conventional approaches that focus on the delivery of EGCG via the blood. Localization of EGCG in the lymph and lymph nodes could offer superior outcomes. Therefore, Topical EGCG-MAX could be VERY useful either alone or in combination with conventional therapeutics for the treatment of all cancers, leukemias and lymphomas. Further, Topical EGCG-MAX almost completely stops the transmission of chronic pain impulses in the central nervous system.
Molecular mechanisms and imaging of lymphatic metastasis.
Tumor metastasis and the lymphatic vasculature.
From tumor lymphangiogenesis to lymphvascular niche.
Tumor and lymph node lymphangiogenesis–impact on cancer metastasis.
Topical EGCG-MAX allows patients to enjoy the benefits of purified 95% EGCG by applying it directly to their skin in the area(s) where metastasis and primary cancer are found, particularly where the lymph nodes are located. Within one minute after topical application of EGCG-MAX, you could feel the intense sensation in your body. Clearly, topical EGCG-MAX is readily entering the body via a topical application and can kill cancer cells through multiple mechanisms.
